BOSTON--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the appointment of Gerald Quirk as General Counsel and Executive Vice President, Business Operations. Mr. Quirk brings to Tokai more than twenty years of experience advancing the legal and business interests of public biopharmaceutical companies, including the development and commercialization of oncology products.